Physician profile
Lori A Ray
NPI 1376616771
$1,065.74
in general payments reported to CMS, 2019-2025
22 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $203 · 2021: $96.23 · 2022: $120 · 2023: $138 · 2024: $126 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $222.12 | 2020-2022 | |
| Abbvie INC. | $183.39 | 2021-2025 | |
| Novo Nordisk INC | $109.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Seqirus USA INC | $68.26 | 2019-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Astrazeneca Pharmaceuticals LP | $65.44 | 2019-2024 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.19 | 2025 | Xifaxan |
| Abbott Laboratories | $47.56 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $39.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.11 | 2019 | |
| Merck Sharp & Dohme LLC | $36.03 | 2022-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Philips North America LLC | $28.87 | 2019 | |
| Daiichi Sankyo INC. | $25.31 | 2023 | Injectafer |
| Amgen INC. | $21.13 | 2024 | Otezla |
| Lilly USA, LLC | $19.25 | 2025 | Zepbound |
| Otsuka America Pharmaceutical, INC. | $18.96 | 2023 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $15.31 | 2023 | Krystexxa |
| Endogastric Solutions, INC | $15.25 | 2023 | Esophyx |
| Cranial Technologies, INC | $12.78 | 2019 | |
| Pfizer INC. | $12.61 | 2019 | |
| Glaxosmithkline, LLC. | $12.49 | 2019 | |
| Genentech USA, INC. | $12.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.